Effect of treatment period with LC478, a disubstituted adamantayl derivative, on P-glycoprotein inhibition: its application to increase docetaxel absorption in rats

References

• Alam A, Kowal J, Broude E, et al. (2019). Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 363:753–6.
   PubMed Web of Science ®Google Scholar
• Aqarwal SK, Hu B, Chien D, et al. (2016). Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol 56:1335–43.
   PubMed Web of Science ®Google Scholar
• Bae JK, Kim YJ, Chae HS, et al. (2017). Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition. Xenobiotica 47:450–9.
   PubMed Web of Science ®Google Scholar
• Baker J, Ajani J, Scotté F, et al. (2008). Docetaxel-related side effects and their management. Eur J Oncol Nurs 12:253–68.
   PubMed Web of Science ®Google Scholar
• Baker SD, Sparreboom A, Verweij J. (2006). Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45:235–52.
   PubMed Web of Science ®Google Scholar
• Bhutto ZA, He F, Zloh M, et al. (2018). Use of quercetin in animal feed: effects on the P-gp expression and pharmacokinetics of orally administrated enrofloxacin in chicken. Sci Rep 8:4400.
   PubMed Web of Science ®Google Scholar
• Callaghan R, Luk F, Bebawy M. (2014). Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 42:623–31.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792–5.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yoon I, Kim TG, Lee MG. (2012). Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein–calorie malnutrition. Xenobiotica 42:442–55.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu AM. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793–807.
   PubMed Web of Science ®Google Scholar
• Crommentuyn KM, Schellens JH, van den Berg JD, Beijnen JH. (1998). In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 24:345–66.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–109.
   PubMed Web of Science ®Google Scholar
• Dou L, Mai Y, Madla CM, et al. (2018). P-glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food. Eur J Pharm Sci 123:569–75.
   PubMed Web of Science ®Google Scholar
• Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth. Enzymol 249:61–90.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York, NY: Marcel–Dekker, 494.
   Google Scholar
• Han SY, Lu Q, Lee K, Choi YH. (2019). LC478, a novel di-substituted adamantyl derivative, enhances the oral bioavailability of docetaxel in rats. Pharmaceutics 11:135.
   Web of Science ®Google Scholar
• Jaramillo AC, Saig FA, Cloos J, et al. (2018). How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? Cancer Drug Resist 1:6–29.
   Google Scholar
• Jin X, Luong T, Reese N, et al. (2014). Comparision of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods 70:188–94.
   PubMed Web of Science ®Google Scholar
• Kadioglu O, Saeed ME, Valoti M, et al. (2016). Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: functional and molecular docking analyses. Biochem Pharmacol 104:42–51.
   PubMed Web of Science ®Google Scholar
• Kilkenny C, Browne WJ, Cuthill IC, et al. (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577–9.
   PubMed Web of Science ®Google Scholar
• Kim Y, Chen J. (2018). Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science 359:915–9.
   PubMed Web of Science ®Google Scholar
• Kim TE, Lee H, Lim KS, et al. (2014). Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol 78:556–64.
   PubMed Web of Science ®Google Scholar
• Kwak JO, Lee SH, Lee GS, et al. (2010). Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 627:92–8.
   PubMed Web of Science ®Google Scholar
• Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–40.
   PubMedGoogle Scholar
• Lee YK, Han SY, Chin YW, Choi YH. (2012). Effects of cysteine on the pharmacokinetics of paclitaxel in rats. Arch Pharm Res 35:509–16.
   PubMed Web of Science ®Google Scholar
• Li-Blatter X, Beck A, Seelig A. (2012). P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J 102:1383–93.
   PubMed Web of Science ®Google Scholar
• Li J, Jaimes KF, Aller SG. (2014). Refined structures of mouse P-glycoprotein. Protein Sci 23:34–46.
   PubMed Web of Science ®Google Scholar
• Li XQ, Wang L, Lei Y, et al. (2015). Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Eur J Med Chem 101:560–72.
   PubMed Web of Science ®Google Scholar
• Min KH, Xia Y, Kim EK, et al. (2009). A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives. Bioorg Med Chem Lett 19:5376–9.
   PubMed Web of Science ®Google Scholar
• Montanari F, Ecker GF. (2015). Prediction of drug-ABC-transporter interaction: recent advances and future challenges. Adv Drug Deliv Rev 86:17–26.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. (2009). AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–91.
   PubMed Web of Science ®Google Scholar
• Rapposelli S, Coi A, Imbriani M, Bianucci AM. (2012). Development of classification models for identifying “true” P-glycoprotein (P-gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays. Int J Mol Sci 13:6924–43.
   PubMed Web of Science ®Google Scholar
• Saaby L, Brodin B. (2017). A critical view on in vitro analysis of P-glycoprotein (P-gp) transport kinetics. J Pharm Sci 106:2257–64.
   PubMed Web of Science ®Google Scholar
• Saneja A, Khare V, Alam N, et al. (2014). Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv 11:121–38.
   PubMed Web of Science ®Google Scholar
• Simon S, Schubert R. (2012). Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements. Biochim Biophys Acta 1821:1211–23.
   PubMed Web of Science ®Google Scholar
• Sohail MF, Rehman M, Sarwar HS, et al. (2018). Advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine 13:3145–61.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1998). Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1–17.
   PubMed Web of Science ®Google Scholar
• Stephens RH, O‘Neill CA, Warhurst A, et al. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584–91.
   PubMed Web of Science ®Google Scholar
• Taub ME, Podila L, Ely D, Almeida I. (2005). Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33:1679–87.
   PubMed Web of Science ®Google Scholar
• Thummel KE. (2007). Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117:3173–6.
   PubMed Web of Science ®Google Scholar
• Wang T, Sun Y, Ma W, et al. (2015). Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo. Mol Pharm 12:1–9.
   PubMedGoogle Scholar
• Wilkinson GR, Shand DG. (1975). Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–90.
   PubMed Web of Science ®Google Scholar
• Yan YD, Kim DH, Sung JH, et al. (2010). Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 399:116–20.
   PubMed Web of Science ®Google Scholar
• Yee KL, Khalilieh SG, Sanchez RI, et al. (2017). The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig 37:659–67.
   PubMed Web of Science ®Google Scholar